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Balanced form: -1, -19, +der(1), +der(19); unbalanced 
form: -19, +der(19). 
Disease 
B Lymphoblastic leukemia/lymphoma with 
t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1); mostly 
found in ALL, L1/L2 type; exceptionally found in L3-
like ALL, T-ALL, NHL, or AML. 
Phenotype/cell stem origin 
Most cases: 'pre B' (cIg+) ALL; may be cIg- or sIg+.  
CD45dim, CD19pos, CD34neg, CD22pos/dim, 
CD20dim/pos, CD24pos, TdTpos, CD10neg/dim, 
cIgMpos, CD9pos, CD15neg, CD65neg, CD66cneg, 
CD13neg, CD33neg. 
Epidemiology 
5% of ALL, or 20% of pre B ALL; found in children 
and young adults (1-60 yrs, median: 10 yrs --> one f 
the most frequent ALL in childhood (4-6%)); 3 male/4 
female patients. 
Clinics 
Moderate organomegaly; frequent CNS involvement; 
blood data: high WBC (median 20 x 109/L); high LDH. 
 
Balanced t(1;19)(q23;p13) (top left) and der(19) t(1;19)(q23;p13) G-banding (bottom left) - Courtesy Jean-Luc Lai; and R-banding (right) 
top: - Editor, below: - Courtesy Christiane Charrin.Clinics and pathology 
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c-PBX1 at 1q23 in normal cells: PAC 1146N1 - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. Laboratories willing to 
validate the probes are wellcome: contact M Rocchi. 
 
Treatment 
Treatment should be adapted to biological features at 
the moment of diagnosis and also to early 
chemotherapy response and risk group stratification 
should not be based on TCF3-PBX1 detection. 
Prognosis 
Although this chromosomal abnormality usually 
discloses adverse prognostic features (WBC, SNC), it 
is associated with good prognosis with modern 
intensive protocols.  
Median 5 yr-event free survival probability in 
childhood ALL: 85(6)%; no age or blood data 
prognostic significance; there are no differences 
between the prognosis of balanced or unbalanced 
forms.  
Prognosis in adults is not different between TCF3-
PBX1 positive and negative cases (pEFS: 40 vs. 44%). 
Cytogenetics 
Cytogenetics morphological 
Breakpoint is in 19p13.3; two different forms (see 
diagrams above): - the balanced t(1;19), one fourth of 
cases, with a der(1) and a der(19); - the unbalanced 
form, found in 3/4 cases, with 2 normal chromosomes 
1, a der(19), and 1 normal chromosome 19: --> partial 
trisomy for 1q23-1qter and monosomy for 19p13.3-
pter; the 2 forms can be in mosaic; note: 19p13 and 
19q13 may be confused (e.g. literature reports). A 
subset of ALL usually hyperdyploid B-ALL has an 
identical t(1;19) that lack the expected phenotype 
probably do not represent TCF3-PBX1 B-ALL. 
Additional anomalies 
t(17;19)(q22;p13) is not stricto sensu a variant, bu so 
far, an equivalent, with HLF (hepatic leukemia factor), 
on 17q22, involved in the translocation. Additional 
anomalies are found in half of the cases, mostly partial 
dup (1q), +6, del(6q), +8, i(9q), +17, i(17q), +21. 
Genes involved and proteins 
Note 
The following are (most often) involved, except in 
some cases lacking the cIg expression: 




Previously known as "pre-B-cell leukemia transcription 
factor 1". 
DNA/RNA 
Alternate splicing (variants 1, 2 and 3) (Acc Numbers: 
NM_001204963.1, NM_001204961.1 and 
NM_002585.3). 
Protein 
Nuclear protein that belongs to the PBX homeobox 
family of transcriptional factors. Contains a 
homeodomain to bind to DNA. 




Other names: bHLHb21, E2A, "E2A immunoglobulin 
enhancer-binding factor E12/E47", E47, 
"immunoglobulin transcription factor 1", ITF1, "kappa-
E2-binding factor", MGC129647, MGC129648, 
"transcription factor E2-alpha", VDIR, "VDR 
interacting repressor". 
DNA/RNA 
Alternate splicing 2 isoforms --> E12 and E47. 
Alternatively spliced transcript variants encoding 
multiple isoforms have been observed for this gene, 
and a pseudogene of this gene is located on the short 
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Protein 
Contains transcriptional activation domains and a basic 
helix-loop-helix DNA binding site; binds specifically to 
an immunoglobulin enhancer; nuclear localization; 
transcription factor. 




5' TCF3 exons fused to 3' PBX1; breakpoints are 
clustered on both genes; the reciprocal 5' PBX1 - 3' 
E2A is not transcribed. 
Transcript 
Most cases present fusion of exons 1-16 in TCF3 to 
exons 4-9 in PBX1. 
Alternative breakpoint in intron 4 of PBX1, not 




550 amino acids; 85 kDa; N-term transcriptional 
activation domains from TCF3 fused to the Hox 
cooperative motif and homeodomain of C-term PBX1; 
potent transcriptional activator. 
Expression / Localisation 
Nuclear localisation. 
Oncogenesis 
Pleiotropic transforming activity.  
The resulting fusion protein (TCF3-PBX1), in which 
the DNA binding domain of E2A is replaced by the 
DNA binding domain of TCF3, transforms cells by 
constitutively activating transcription of genes 
regulated by PBX1 or by other members the PBX 
protein family. 
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